- Home
- DOYU vs KMDA Comparison
DOYU vs KMDA Comparison
Compare DOYU & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- KMDA
- Stock Information
- Founded
- DOYU 2014
- KMDA 1990
- Country
- DOYU China
- KMDA Israel
- Employees
- DOYU 1336
- KMDA N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- KMDA Health Care
- Exchange
- DOYU Nasdaq
- KMDA Nasdaq
- Market Cap
- DOYU 352.1M
- KMDA 310.1M
- IPO Year
- DOYU 2019
- KMDA N/A
- Fundamental
- Price
- DOYU $10.88
- KMDA $5.94
- Analyst Decision
- DOYU Sell
- KMDA Strong Buy
- Analyst Count
- DOYU 4
- KMDA 2
- Target Price
- DOYU $7.03
- KMDA $14.50
- AVG Volume (30 Days)
- DOYU 136.9K
- KMDA 40.9K
- Earning Date
- DOYU 12-05-2024
- KMDA 11-13-2024
- Dividend Yield
- DOYU N/A
- KMDA N/A
- EPS Growth
- DOYU N/A
- KMDA 230.67
- EPS
- DOYU N/A
- KMDA 0.25
- Revenue
- DOYU $650,466,712.00
- KMDA $154,574,000.00
- Revenue This Year
- DOYU N/A
- KMDA $14.85
- Revenue Next Year
- DOYU N/A
- KMDA $7.64
- P/E Ratio
- DOYU N/A
- KMDA $22.94
- Revenue Growth
- DOYU N/A
- KMDA 6.01
- 52 Week Low
- DOYU $6.29
- KMDA $4.58
- 52 Week High
- DOYU $20.17
- KMDA $6.53
- Technical
- Relative Strength Index (RSI)
- DOYU 58.62
- KMDA 77.16
- Support Level
- DOYU $10.53
- KMDA $5.84
- Resistance Level
- DOYU $11.13
- KMDA $6.06
- Average True Range (ATR)
- DOYU 0.52
- KMDA 0.12
- MACD
- DOYU 0.21
- KMDA 0.07
- Stochastic Oscillator
- DOYU 91.14
- KMDA 91.57
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.